Literature DB >> 9670963

Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection.

A J Godkin1, M P Davenport, A Willis, D P Jewell, A V Hill.   

Abstract

In diseases with a strong association with an HLA haplotype, identification of relevant T cell epitopes may allow alteration of the pathologic process. In this report we use a reverse immunogenetic approach to predict possible HLA class II-restricted T cell epitopes by using complete pool sequencing data. Data from HLA-DR2(B1*1501), -DR3(B1*0301), -DQ2(A1*0501, B1*0201), and -DQ8(A1*0301, B1*0302) alleles were used by a computer program that searches a candidate protein to predict ligands with a relatively high probability of being processed and presented. This approach successfully identified both known T cell epitopes and eluted single peptides from the parent protein. Furthermore, the program identified ligands from proteins in which the binding motif of the HLA molecule was unable to do so. When the information from the nonbinding N- and C-terminal regions in the pool sequence was removed, the ability to predict several ligands was markedly reduced, particularly for the HLA-DQ alleles. This suggests a possible role for these regions in determining ligands for HLA class II molecules. Thus, the use of complete eluted peptide sequence data offers a powerful approach to the prediction of HLA-DQ and -DR peptide ligands and T cell epitopes.

Mesh:

Substances:

Year:  1998        PMID: 9670963

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Modeling the structure of bound peptide ligands to major histocompatibility complex.

Authors:  Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

2.  Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules.

Authors:  Sergio Madurga; Ignasi Belda; Xavier Llorà; Ernest Giralt
Journal:  Protein Sci       Date:  2005-08       Impact factor: 6.725

3.  Immunopathogenesis of celiac disease.

Authors:  Jason Tye-Din; Robert Anderson
Journal:  Curr Gastroenterol Rep       Date:  2008-10

4.  Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and -protective HLA class II molecules.

Authors:  T P Astill; R J Ellis; S Arif; T I M Tree; M Peakman
Journal:  Diabetologia       Date:  2003-04-09       Impact factor: 10.122

5.  Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population.

Authors:  John Sidney; Amiyah Steen; Carrie Moore; Sandy Ngo; Jolan Chung; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

6.  Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection.

Authors:  G C Harcourt; M Lucas; A J Godkin; M Kantzanou; R E Phillips; P Klenerman
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

7.  Prediction of HLA-DQ8beta cell peptidome using a computational program and its relationship to autoreactive T cells.

Authors:  Kuan Y Chang; Emil R Unanue
Journal:  Int Immunol       Date:  2009-05-21       Impact factor: 4.823

Review 8.  The versatility of the αβ T-cell antigen receptor.

Authors:  Mugdha Bhati; David K Cole; James McCluskey; Andrew K Sewell; Jamie Rossjohn
Journal:  Protein Sci       Date:  2014-01-28       Impact factor: 6.725

9.  Flanking residues are central to DO11.10 T cell hybridoma stimulation by ovalbumin 323-339.

Authors:  Benjamin M Roy; Dmitriy V Zhukov; Jennifer A Maynard
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

10.  Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough.

Authors:  Christopher J Holland; David K Cole; Andrew Godkin
Journal:  Front Immunol       Date:  2013-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.